KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizationCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in TaxesDivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and Equipment
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Gsk (GSK) over the last 17 years, with Q4 2025 value amounting to $1.2 billion.

  • Gsk's Net Cash Flow rose 2385.51% to $1.2 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $1.3 billion, marking a year-over-year decrease of 1308.17%. This contributed to the annual value of $1.4 billion for FY2025, which is 4452.04% down from last year.
  • Per Gsk's latest filing, its Net Cash Flow stood at $1.2 billion for Q4 2025, which was up 2385.51% from -$439.8 million recorded in Q3 2025.
  • Over the past 5 years, Gsk's Net Cash Flow peaked at $11.0 billion during Q3 2021, and registered a low of -$9.5 billion during Q3 2022.
  • Its 5-year average for Net Cash Flow is $1.0 billion, with a median of $342.6 million in 2023.
  • In the last 5 years, Gsk's Net Cash Flow tumbled by 96984.5% in 2021 and then surged by 131419.83% in 2025.
  • Quarter analysis of 5 years shows Gsk's Net Cash Flow stood at $6.2 billion in 2021, then plummeted by 65.94% to $2.1 billion in 2022, then crashed by 85.38% to $307.8 million in 2023, then surged by 213.99% to $966.5 million in 2024, then rose by 23.86% to $1.2 billion in 2025.
  • Its Net Cash Flow stands at $1.2 billion for Q4 2025, versus -$439.8 million for Q3 2025 and -$752.4 million for Q2 2025.